ArticleOncotarget2017
Long noncoding RNA PVT1 inhibits renal cancer cell apoptosis by up-regulating Mcl-1.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Prognostic significance of long non-coding RNAs in clear cell renal cell carcinoma: A meta-analysis.Medicine · 2019Pooled it
- Targeting the lncRNA PVT-1-Hippo signaling axis in kidney diseases: an emerging therapeutic paradigm.Molecular biology reports · 2026Review
- Exploring the oncogenic mechanism of plasmacytoma variant translocation 1 (PVT1) gene in solid cancers; emphasis on microRNA regulation pathways.Cancer cell international · 2026Review
- Common molecular links and therapeutic insights between type 2 diabetes and kidney cancer.PloS one · 2025Article
- An immune infiltration-related prognostic model of kidney renal clear cell carcinoma with two valuable markers: CAPN12 and MSC.Frontiers in oncology · 2023Article
- lncRNA PVT1: a novel oncogene in multiple cancers.Cellular & molecular biology letters · 2022Review
- LncRNA PVT1 is increased in renal cell carcinoma and affects viability and migration in vitro.Journal of clinical laboratory analysis · 2022Article
- Analysis of anti-apoptotic PVT1 oncogene and apoptosis-related proteins (p53, Bcl2, PD-1, and PD-L1) expression in thyroid carcinoma.Journal of clinical laboratory analysis · 2022Article
- Long non-coding RNA plasmacytoma variant translocation 1 and growth arrest specific 5 regulate each other in osteoarthritis to regulate the apoptosis of chondrocytes.Bioengineered · 2022Article
- Role of Metabolic Reprogramming of Long non-coding RNA in Clear Cell Renal Cell Carcinoma.Journal of Cancer · 2022Review
- The Effect of lncRNA-PVT1 on Liver Cancer Rats by Regulating the Expression of MMP9.BioMed research international · 2022Article
- Myeloid cell leukemia-1: a formidable barrier to anticancer therapeutics and the quest of targeting it.Exploration of targeted anti-tumor therapy · 2022Review
- Comprehensive analysis of lncRNAs as biomarkers for diagnosis, prognosis, and treatment response in clear cell renal cell carcinoma.Molecular therapy oncolytics · 2021Article
- Positive feedback regulation of lncRNA PVT1 and HIF2α contributes to clear cell renal cell carcinoma tumorigenesis and metastasis.Oncogene · 2021Article
- Review
- LncRNAs Act as a Link between Chronic Liver Disease and Hepatocellular Carcinoma.International journal of molecular sciences · 2020Review
- Silencing lncRNAs PVT1 Upregulates miR-145 and Confers Inhibitory Effects on Viability, Invasion, and Migration in EC.Molecular therapy. Nucleic acids · 2020Article
- Saga of Mcl-1: regulation from transcription to degradation.Cell death and differentiation · 2020Review
- HIF-1α suppresses myeloma progression by targeting Mcl-1.International journal of clinical and experimental pathology · 2020Article
- Down-regulation of long noncoding RNA PVT1 inhibits esophageal carcinoma cell migration and invasion and promotes cell apoptosis via microRNA-145-mediated inhibition of FSCN1.Molecular oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long non-coding RNA plasmacytoma variant translocation 1 (PVT1) is up-regulated in various human cancers, and our results indicated that PVT1 was up-regulated in clear cell renal cell carcinoma tissues. The Cancer Genome Atlas cohort analysis revealed that in clear cell renal cell carcinoma, higher PVT1 expression correlated with advanced TNM stage, histological grade, and poor survival. PVT1 knockdown promoted apoptosis, inhibited renal cancer cell proliferation, decreased Mcl-1, and increased cleaved caspase-3 and cleaved PARP. PVT1 increased Mcl-1 mRNA levels in renal cancer cells by promoting mRNA stability without influencing its transcription.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.